Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1992 Jan 1;175(1):139–146. doi: 10.1084/jem.175.1.139

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells

PMCID: PMC2119086  PMID: 1309851

Abstract

Inoculated immunogenic cancer cells after initial growth are potentially rejected by specific host immunity; however, the outcome of the interaction between host and inoculated cancer cells is a function of multiple factors including the route of inoculation, the number of cells, the density of antigens on the injected cancer cells, and the state of the immune system of the host. In the present study, we have examined a different kind of variable: the stroma that inoculated tumor cells initially reside in. The impetus to examine this factor arises from observations that cancer cells from several lines inoculated as fragments of solid tumors often grow progressively, whereas the same number or more than 10-fold larger numbers of identical type cells injected as a suspension are rejected, even though fragments or suspended cells are both tumorigenic at the same doses in nude mice. In the present studies, we found that: (a) indeed, cancer cells inoculated as fragments were more tumorigenic than cancer cells in suspension; (b) the tumorigenicity of suspended cancer cells was increased by injection of the cells into polyurethane sponge implants; (c) cancer cells were more tumorigenic embedded in syngeneic stroma than in transgenic antigenic stroma expressing the K216 major histocompatibility complex class I antigen; and (d) antigenic, bone marrow-derived, stromal components (presumably passenger leukocytes) were sufficient to cause rejection of immunogenic but antigenically unrelated cancer.(ABSTRACT TRUNCATED AT 250 WORDS)

Full Text

The Full Text of this article is available as a PDF (799.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Applegate K. G., Balch C. M., Pellis N. R. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes. Cancer Res. 1990 Nov 15;50(22):7153–7158. [PubMed] [Google Scholar]
  2. Champlin R., Gale R. P. Acute myelogenous leukemia: recent advances in therapy. Blood. 1987 Jun;69(6):1551–1562. [PubMed] [Google Scholar]
  3. Dvorak H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986 Dec 25;315(26):1650–1659. doi: 10.1056/NEJM198612253152606. [DOI] [PubMed] [Google Scholar]
  4. Evans G. A., Margulies D. H., Shykind B., Seidman J. G., Ozato K. Exon shuffling: mapping polymorphic determinants on hybrid mouse transplantation antigens. Nature. 1982 Dec 23;300(5894):755–757. doi: 10.1038/300755a0. [DOI] [PubMed] [Google Scholar]
  5. Fisher M. S., Kripke M. L. Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1688–1692. doi: 10.1073/pnas.74.4.1688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Garin-Chesa P., Old L. J., Rettig W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235–7239. doi: 10.1073/pnas.87.18.7235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kripke M. L., Thorn R. M., Lill P. H., Civin C. I., Pazmiño N. H., Fisher M. S. Further characterization of immunological unresponsiveness induced in mice by ultraviolet radiation. Growth and induction of nonultraviolet-induced tumors in ultraviolet-irradiated mice. Transplantation. 1979 Sep;28(3):212–217. doi: 10.1097/00007890-197909000-00012. [DOI] [PubMed] [Google Scholar]
  8. Lee D. R., Rubocki R. J., Lie W. R., Hansen T. H. The murine MHC class I genes, H-2Dq and H-2Lq, are strikingly homologous to each other, H-2Ld, and two genes reported to encode tumor-specific antigens. J Exp Med. 1988 Nov 1;168(5):1719–1739. doi: 10.1084/jem.168.5.1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Morison W. L., Jerdan M. S., Hoover T. L., Farmer E. R. UV radiation-induced tumors in haired mice: identification as squamous cell carcinomas. J Natl Cancer Inst. 1986 Nov;77(5):1155–1162. [PubMed] [Google Scholar]
  10. Mullen C. A., Urban J. L., Van Waes C., Rowley D. A., Schreiber H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J Exp Med. 1985 Nov 1;162(5):1665–1682. doi: 10.1084/jem.162.5.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Perdrizet G. A., Ross S. R., Stauss H. J., Singh S., Koeppen H., Schreiber H. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J Exp Med. 1990 Apr 1;171(4):1205–1220. doi: 10.1084/jem.171.4.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Philipps C., McMillan M., Flood P. M., Murphy D. B., Forman J., Lancki D., Womack J. E., Goodenow R. S., Schreiber H. Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule. Proc Natl Acad Sci U S A. 1985 Aug;82(15):5140–5144. doi: 10.1073/pnas.82.15.5140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ramrakha P. S., Sharp R. J., Yeoman H., Stanley M. A. The influence of MHC-compatible and MHC-incompatible antigen-presenting cells on the survival of MHC-compatible cultured murine keratinocyte allografts. Transplantation. 1989 Oct;48(4):676–680. [PubMed] [Google Scholar]
  14. Stauss H. J., Linsk R., Fischer A., Watts S., Banasiak D., Haberman A., Clark I., Forman J., McMillan M., Schreiber H. Isolation of the MHC genes encoding the tumour-specific class I antigens expressed on a murine fibrosarcoma. J Immunogenet. 1986 Apr-Jun;13(2-3):101–111. doi: 10.1111/j.1744-313x.1986.tb01090.x. [DOI] [PubMed] [Google Scholar]
  15. Stauss H. J., Van Waes C., Fink M. A., Starr B., Schreiber H. Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J Exp Med. 1986 Nov 1;164(5):1516–1530. doi: 10.1084/jem.164.5.1516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Urban J. L., Burton R. C., Holland J. M., Kripke M. L., Schreiber H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med. 1982 Feb 1;155(2):557–573. doi: 10.1084/jem.155.2.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Van Waes C., Urban J. L., Rothstein J. L., Ward P. L., Schreiber H. Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells. J Exp Med. 1986 Nov 1;164(5):1547–1565. doi: 10.1084/jem.164.5.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ward P. L., Koeppen H. K., Hurteau T., Rowley D. A., Schreiber H. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 1990 Jul 1;50(13):3851–3858. [PubMed] [Google Scholar]
  19. Ward P. L., Koeppen H., Hurteau T., Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med. 1989 Jul 1;170(1):217–232. doi: 10.1084/jem.170.1.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. van den Hooff A. Stromal involvement in malignant growth. Adv Cancer Res. 1988;50:159–196. doi: 10.1016/s0065-230x(08)60437-6. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES